Advanced Oncotherapy (FRA:R3I1) FCF Margin % : 0.00% (As of Jun. 2022)

View and export this data going back to 2018. Start your Free Trial

What is Advanced Oncotherapy FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Advanced Oncotherapy's Free Cash Flow for the six months ended in Jun. 2022 was €-14.54 Mil. Advanced Oncotherapy's Revenue for the six months ended in Jun. 2022 was €0.00 Mil. Therefore, Advanced Oncotherapy's FCF Margin % for the quarter that ended in Jun. 2022 was 0.00%.

As of today, Advanced Oncotherapy's current FCF Yield % is 0.00%.

The historical rank and industry rank for Advanced Oncotherapy's FCF Margin % or its related term are showing as below:

FRA:R3I1's FCF Margin % is not ranked ^*
in the Medical Devices & Instruments industry.
Industry Median: -7.11
* Ranked among companies with meaningful FCF Margin % only.

Advanced Oncotherapy FCF Margin % Historical Data

The historical data trend for Advanced Oncotherapy's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Advanced Oncotherapy FCF Margin % Chart

Advanced Oncotherapy Annual Data

Trend

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

FCF Margin %

Get a 7-Day Free Trial

Advanced Oncotherapy Semi-Annual Data
	Dec12	Jun13	Dec13	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22
FCF Margin %	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Advanced Oncotherapy's FCF Margin %

For the Medical Devices subindustry, Advanced Oncotherapy's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Advanced Oncotherapy's FCF Margin % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Advanced Oncotherapy's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Advanced Oncotherapy's FCF Margin % falls into.

Advanced Oncotherapy FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Advanced Oncotherapy's FCF Margin for the fiscal year that ended in Dec. 2021 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2021 )	/	Revenue (A: Dec. 2021 )
	=	-45.739	/	0
	=	%

Advanced Oncotherapy's FCF Margin for the quarter that ended in Jun. 2022 is calculated as

FCF Margin	=	Free Cash Flow (Q: Jun. 2022 )	/	Revenue (Q: Jun. 2022 )
	=	-14.543	/	0
	=	%

Advanced Oncotherapy FCF Margin % Related Terms

Thank you for viewing the detailed overview of Advanced Oncotherapy's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Advanced Oncotherapy (FRA:R3I1) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Advanced Oncotherapy PLC (FRA:R3I1) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

4 Tenterden Street, Third Floor, London, GBR, W1S 1TE

Website

https://www.avoplc.com

Advanced Oncotherapy PLC is active in the healthcare domain in the United Kingdom. As a medical care provider, its focus is to develop technologies to maximize the destructive effect of radiation on tumors whilst minimizing damage to healthy tissues. It develops an affordable proton-based radiotherapy system, using innovative and clinically effective technology, thereby contributing to curing critical unmet conditions. The company's only business segment is Proton Therapy.

Advanced Oncotherapy (FRA:R3I1) Headlines

No Headlines